Public Company News

Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China

SHANGHAI and SUZHOU, China, March 22, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors (study No. 4003.2). This study w...

2021-03-22 10:31 5339

FICO Survey: 71% of Taiwanese Prefer to Use Digital Channels to Engage with their Bank During Financial Hardship

Appeal of in-person branch banking fading fast post pandemic TAIPEI, Taiwan, March 22, 2021 /PRNewswire/ -- Preferred banking customer touchpoints across Asia Pacific - December 2020 Highlights: * 71 percent o...

2021-03-22 08:30 7023

Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

SHANGHAI and GAITHERSBURG, Md., March 22, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in hematolog...

2021-03-22 08:00 3694